Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer by shutting down one of cancer's most commonly mutated pathways.
We’re proud to join Erasca in a strategic research and development collaboration to evaluate multiple agents from their pipeline targeting the RAS/MAPK pathway.
Learn more: fal.cn/3rgJV@Erasca@SKopetz@DavidHongMD#EndCancer
Please join us for the @Erasca Virtual R&D Day on Lead Clinical Programs ERAS-007 & ERAS-601 in Advanced Solid Tumors featuring Dr. David Hong (MD Anderson Cancer Center). A live Q&A session will follow. Register Here: lifesci.events/ERAS2
A big, warm welcome to the @erascainc team! 👏👏👏
Erasca, Inc. joins us in Times Square to ring the @Nasdaq Opening Bell in honor of their IPO. 🎉 #EraseCancer
Welcome to the @Nasdaq family, @erascainc!
Erasca, Inc. is a clinical-stage precision oncology company driven by a bold mission: to erase cancer by shutting down one of cancer's most commonly mutated pathways. #EraseCancer
Now trading: $ERAS
.@erascainc is a clinical-stage precision oncology company driven by a bold mission—to erase cancer. We speak with CEO Jonathan E. Lim, M.D., about the company’s vision. xitter.cf/i/broadcasts/1YqGoypaX…